Testosterone Suppression With Luteinizing Hormone ‐Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer

ConclusionsAn undetectable PSA does not rule out the presence of higher than desired levels of testosterone during ADT. In this cohort of patients, there appears to be no impact of testosterone escape on either biochemical relapse‐free survival or overall survival.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Original Research Article Source Type: research